Savant Capital LLC Sells 3,452 Shares of IDEXX Laboratories, Inc. $IDXX

Savant Capital LLC cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 79.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 914 shares of the company’s stock after selling 3,452 shares during the quarter. Savant Capital LLC’s holdings in IDEXX Laboratories were worth $618,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Virtus Advisers LLC bought a new position in shares of IDEXX Laboratories during the third quarter valued at $26,000. Park Place Capital Corp bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at $29,000. Mowery & Schoenfeld Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 58.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after acquiring an additional 20 shares during the period. WealthCollab LLC bought a new position in shares of IDEXX Laboratories during the second quarter valued at $30,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of IDEXX Laboratories during the third quarter valued at $36,000. 87.84% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on IDXX shares. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Barclays lowered their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Stifel Nicolaus lowered their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Finally, Piper Sandler lowered their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $560.73 on Thursday. IDEXX Laboratories, Inc. has a twelve month low of $506.91 and a twelve month high of $769.98. The firm has a market cap of $44.23 billion, a PE ratio of 41.29, a price-to-earnings-growth ratio of 3.20 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The business has a fifty day moving average of $563.43 and a 200-day moving average of $633.51.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period last year, the company posted $2.91 earnings per share. The firm’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.